Cargando…
ODP607 Long-term Efficacy of Setmelanotide in Patients With POMC or LEPR Deficiency Obesity
The melanocortin-4 receptor (MC4R) pathway in the brain is responsible for energy regulation, affecting appetite and body weight. Impairments of this pathway can result in hyperphagia (insatiable hunger) and obesity. The MC4R can be impacted by the POMC, PCSK1, or LEPR genes. Variants in these genes...
Autores principales: | Clément, Karine, Wabitsch, Martin, Van den Akker, Erica, Argente, Jesús, Scimia, Ceclila, Srinivasan, Madhura, Yuan, Guojun, Kühnen, Peter |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9624830/ http://dx.doi.org/10.1210/jendso/bvac150.030 |
Ejemplares similares
-
Timing of Onset of Adverse Events With Setmelanotide, an MC4R Agonist, in Patients With Severe Obesity Due to LEPR or POMC Deficiency
por: Clément, Karine, et al.
Publicado: (2021) -
RF24 | PSUN96 Setmelanotide in Patients With Heterozygous POMC, LEPR, SRC1, or SH2B1 Obesity: Design of EMANATE – A Placebo-Controlled Phase 3 Trial
por: Wabitsch, Martin, et al.
Publicado: (2022) -
OR10-1 Body Mass Index and Weight Reductions in Patients With Obesity Due to Heterozygous Variants in POMC, PCSK1, and LEPR After 1 Year of Setmelanotide
por: Farooqi, Sadaf, et al.
Publicado: (2022) -
RF24 | PSUN91 Body Mass Index and Weight Reduction in Patients With SH2B1 Genetic Variant Obesity After One Year of Setmelanotide
por: Argente, Jesús, et al.
Publicado: (2022) -
ODP605 Body Mass Index and Weight Reductions in Patients With SRC1 Genetic Variant Obesity After 1 Year of Setmelanotide
por: Martos-Moreno, Gabriel Á, et al.
Publicado: (2022)